President & CEO
2011 to Present
Menlo Park, CA
2010 to 2010
President & CEO
2009 to 2010
South San Francisco, CA
Co-Founder & CEO
2001 to 2008
Covance Biotechnology Services, Inc.
Founder & Director
1993 to 2001
Research Triangle Park, NC
Sensus Drug Development Corportion
Founder & CEO
1992 to 2001
Novo Nordisk Pharmaceucticals, Inc.
SVP, Medical and Scientific Affairs; Head, North American Clinical Development Center
1991 to 1993
Greenwich Pharmaceuticals, Inc.
Vice President, Clinical Development
1985 to 1990
Hospital of the University of Pennsylvania
Adjunct Assistant Professor of Medicine
1982 to 1986
McNeil Pharmaceuticals (Johnson & Johnson)
Director, Medical Research & Services
1982 to 1985
Spring House, PA
1980 to 1982
University of Colorado
Endocrinology & Diabetes Fellowship
1980 to 1982
Hospital of University of Pennsylvania
Internal Medicine Residency Program
1977 to 1980
University of Chicago - The Pritzker School of Medicine
MD with Honors
1973 to 1977
1969 to 1973
As President and CEO is leading Geron, a publicly traded, de-velopment stage biotechnology company after a strategic rea-lignment that has emphasized development of its first-in-class oncology drugs, and divestiture of its embryonic stem cell as-sets. As President and CEO is leading Geron, a publicly traded, de-velopment stage biotechnology company after a strategic rea-lignment that has emphasized development of its first-in-class oncology drugs, and divestiture of its embryonic stem cell as-sets.
What company does John MD work for?
John MD works for Geron Corporation
What is John MD's role at Geron Corporation?
John MD is President & CEO
What industry does John MD work in?
John MD works in the Biotechnology industry.
President & CEO @ As President and CEO is leading Geron, a publicly traded, de-velopment stage biotechnology company after a strategic rea-lignment that has emphasized development of its first-in-class oncology drugs, and divestiture of its embryonic stem cell as-sets. From 2011 to Present (4 years) Menlo Park, CADriver @ From 2010 to 2010 (less than a year) President & CEO @ As President and CEO led Proteolix, a biotechnology company developing proteasome inhibitors (including carfilzomib) for oncology and immunology applications, through a manage-ment realignment and subsequent merger with Onyx Pharma-ceuticals (NASDAQ: ONXX) valued at $856 million. From 2009 to 2010 (1 year) South San Francisco, CACo-Founder & CEO @ As Co-Founder and CEO, led the Company through the ac-quisition, approval and commercialization of two novel endo-crine products (INCRELEX® and SOMATULINE® DEPOT), key partnerships with Genentech and Ipsen S.A., and multiple financing rounds including the IPO in 2004 and subsequent follow-on equity offerings. Tercica merged with Ipsen in the 4th quarter of 2008 in a transaction that valued the company at approximately $660 million. From 2001 to 2008 (7 years) Brisbane, CAFounder & Director @ Developed the business plan and negotiated a joint venture with Corning, Inc., directed site selection and construction of a state-of-the-art, process development and recombinant protein cGMP manufacturing facility in RTP, and as a Director, pro-vided Board oversight for a 450 employee business with multi-ple large pharmaceutical company clients prior to its sale to Akzo Nobel’s Diosynth Division in 2001. From 1993 to 2001 (8 years) Research Triangle Park, NCFounder & CEO @ As Founder and CEO, led the Company through a key part-nership with Genentech, the acquisition, development and ap-proval of an endocrine product, SOMAVERT® (pegvisomant), and the sale of the Company to Pharmacia in 2001. From 1992 to 2001 (9 years) Austin, TXSVP, Medical and Scientific Affairs; Head, North American Clinical Development Center @ Headed up all Phase I-IV clinical development and medical af-fairs activities for pharmaceutical products and devices at NNPI, Novo Nordisk’s largest international subsidiary, and No-vo Nodisk Canada; reported to the CEO of NNPI. From 1991 to 1993 (2 years) Princeton, NJVice President, Clinical Development @ Headed up Phase I-III clinical development for a disease-modifying anti-rheumatic drug, THERAFECTIN®. From 1985 to 1990 (5 years) Greenwich, CTAdjunct Assistant Professor of Medicine @ From 1982 to 1986 (4 years) Philadelphia, PADirector, Medical Research & Services @ Responsible for Phase IIIb and Phase IV clinical programs, medical writing, pharmacovigilence, and medical affairs for McNeil’s marketed products in pain, rheumatology, psychiatry and pancreatic enzyme replacement therapy. Withdrew ZOMAX®, a leading NSAID, from the worldwide market due to serious adverse experiences, and negotiated DESI approval for PARAFON FORTE® with FDA. From 1982 to 1985 (3 years) Spring House, PAAssociate Investigator @ Studied insulin action, the pathophysiology of obesity and type II diabetes, and in vitro, in vivo and clinical effects of pharma-cologic therapies in these disorders; author or co-author of 12 peer-reviewed publications from laboratory of Jerrold Olefsky. From 1980 to 1982 (2 years) Denver, COEndocrinology & Diabetes Fellowship @ University of Colorado From 1980 to 1982 Internal Medicine Residency Program @ Hospital of University of Pennsylvania From 1977 to 1980 MD with Honors @ University of Chicago - The Pritzker School of Medicine From 1973 to 1977 BA, Chemistry @ Earlham College From 1969 to 1973
Extraversion (E), Intuition (N), Thinking (T), Judging (J)
4 year(s), 2 month(s)
There's 73% chance that John MD is seeking for new opportunities
Enjoy unlimited access and discover candidates outside of LinkedIn
Trusted by 400K users from
76% of Fortune 500 companies
The most accurate data ever
Hire Anyone, Anywhere
with ContactOut today
Making remote or global hires? We can help.
No credit card required